Holen Sie sich die Stockscreener-App
78.28
3.22%
2.44
Vorhandelsmarkt:
77.12
-1.16
-1.48%
Schlusskurs vom Vortag:
$75.84
Offen:
$76.47
24-Stunden-Volumen:
383.21K
Relative Volume:
0.84
Marktkapitalisierung:
$5.56B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-22.56
EPS:
-3.47
Netto-Cashflow:
$-153.27M
1W Leistung:
+8.14%
1M Leistung:
-7.05%
6M Leistung:
-0.86%
1J Leistung:
+3.79%
1-Tages-Spanne:
$76.32
$78.61
1-Wochen-Bereich:
$74.17
$78.61
52-Wochen-Spanne:
$61.80
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
78.28 | 5.56B | 0 | -224.29M | -153.27M | -3.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Nuvalent’s (NUVL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Nuvalent stock reiterates buy rating on FDA approval potential - MSN
Nuvalent CEO Porter James Richard sells shares worth $2.05m - MSN
JPMorgan Chase & Co. Has $3.55 Million Stake in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter Sells 27,000 Shares - MarketBeat
Nuvalent CEO Porter James Richard sells shares worth $2.05m By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Nuvalent (NASDAQ:NUVL) - MarketBeat
Nuvalent stock reiterates buy rating on FDA approval potential By Investing.com - Investing.com Canada
Nuvalent's SWOT analysis: biotech stock shows promise amid clinical progress - Investing.com Canada
(NUVL) Trading Report - Stock Traders Daily
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent Announces Corporate Updates and Anticipated Milestones for 2025 - Defense World
Nuvalent's SWOT analysis: biotech's lung cancer drug stock shows promise amid risks - Investing.com Australia
Nuvalent's SWOT analysis: biotech's lung cancer drug stock shows promise amid risks By Investing.com - Investing.com South Africa
Nuvalent’s (NUVL) Outperform Rating Reaffirmed at Wedbush - Defense World
Nuvalent (NASDAQ:NUVL) Given "Outperform" Rating at Wedbush - MarketBeat
Nuvalent chief legal officer sells shares worth $236,182 By Investing.com - Investing.com Nigeria
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones - Yahoo Finance
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipate - GuruFocus.com
Nuvalent To Share Updated Data From ARROS-1, ALKOVE-1 Trials In September - RTTNews
Nuvalent: A Logical Acquisition Target (NASDAQ:NUVL) - Seeking Alpha
Nuvalent's chief development officer sells shares worth $320,009 By Investing.com - Investing.com Australia
Nuvalent's chief development officer sells shares worth $320,009 - Investing.com India
Nuvalent chief scientific officer sells shares worth $197,853 - Investing.com India
Nuvalent chief scientific officer sells shares worth $197,853 By Investing.com - Investing.com Canada
Nuvalent CEO James Porter sells shares worth $1.38 million By Investing.com - Investing.com Australia
Nuvalent, Inc. (NASDAQ:NUVL) CFO Sells $319,994.88 in Stock - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $197,845.44 in Stock - MarketBeat
Nuvalent chief legal officer sells shares worth $236,182 - Investing.com India
Nuvalent CFO Alexandra Balcom sells $320,009 in stock By Investing.com - Investing.com Canada
Nuvalent’s chief development officer sells shares worth $320,009 By Investing.com - Investing.com Nigeria
Nuvalent CEO James Porter sells shares worth $1.38 million - Investing.com
Nuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Principal Financial Group Inc. - Defense World
Where are the Opportunities in (NUVL) - Stock Traders Daily
Nuvalent to Present New Preclinical Data on HER2-Selective Inhib - GuruFocus.com
HC Wainwright Comments on Nuvalent FY2024 Earnings - Defense World
Nuvalent (NASDAQ:NUVL) Now Covered by Analysts at HC Wainwright - Defense World
Nuvalent stock gains on H.C. Wainwright Buy rating, new target By Investing.com - Investing.com Canada
Nuvalent’s SWOT analysis: promising pipeline drives biotech stock outlook By Investing.com - Investing.com Nigeria
Nuvalent's SWOT analysis: promising pipeline drives biotech stock outlook - Investing.com
Nuvalent's SWOT analysis: promising pipeline drives biotech stock outlook By Investing.com - Investing.com South Africa
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):